BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Anti-CXCR4 (BMS-936564)
Biological: Bortezomib
Biological: Lenalidomide
Biological: Dexamethasone

First Posted Date: 2011-05-25

Last Posted Date: 2016-03-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT01359657

Locations: 🇺🇸
University Of Washington School Of Medicine, Seattle, Washington, United States
🇺🇸
University Of Kansas Cancer Center And Medical Pavillion, Westwood, Kansas, United States
🇺🇸
Dana Faber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Phase I Biomarker Study (BMS-936558)

Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: BMS-936558 (Anti-PD-1)

First Posted Date: 2011-05-24

Last Posted Date: 2021-10-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 119

Registration Number: NCT01358721

Locations: 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Inst, Boston, Massachusetts, United States

and more 10 locations

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Dasatinib
Drug: BMS-833923

First Posted Date: 2011-05-23

Last Posted Date: 2017-03-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT01357655

Locations: 🇺🇸
Tennessee Oncology Pllc, Nashville, Tennessee, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

and more 1 locations

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Active, not recruiting

Conditions: Juvenile Idiopathic Arthritis

First Posted Date: 2011-05-23

Last Posted Date: 2025-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 800

Registration Number: NCT01357668

Locations: 🇺🇸
Local Institution - 0001, Princeton, New Jersey, United States
🇧🇷
Local Institution - 0026, Campinas, São Paulo, Brazil
🇦🇹
Local Institution - 0002, Innsbruck, Austria

and more 23 locations

Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: BMS-914392
Drug: Placebo

First Posted Date: 2011-05-20

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT01356914

Locations: 🇬🇧
Eastbourne General Hospital, Eastbourne, United Kingdom

Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients

Completed

Conditions: Hepatitis B, Chronic

First Posted Date: 2011-05-20

Last Posted Date: 2015-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 230

Registration Number: NCT01356901

Locations: 🇩🇪
Local Institution, Herne, Germany

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Biological: nivolumab

First Posted Date: 2011-05-16

Last Posted Date: 2022-05-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 168

Registration Number: NCT01354431

Locations: 🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸
University Of Maryland, Baltimore, Maryland, United States
🇺🇸
North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States

and more 36 locations

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

Phase 1

Completed

Conditions: End Stage Renal Disease

Interventions: Drug: Apixaban

First Posted Date: 2011-04-22

Last Posted Date: 2016-10-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT01340586

A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials

Completed

Conditions: Hepatitis B

First Posted Date: 2011-04-19

Last Posted Date: 2011-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1097

Registration Number: NCT01337479

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

Phase 3

Completed

Conditions: HIV

Interventions: Drug: Atazanavir Sulphate
Drug: Ritonavir

First Posted Date: 2011-04-14

Last Posted Date: 2018-11-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 160

Registration Number: NCT01335698

Locations: 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇬🇧
Local Institution, Birmingham, WEST Midlands, United Kingdom
🇺🇸
Children'S National Medical Center, Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy